Head-to-head · Cost-Efficiency Index
REMEVi vs NP2GO
Two GLP-1 programs on the bench, scored on the same six factors. Here's how their real cost of ownership compares — and which one we'd start with.
REMEVi
Cost-first shoppers who want bilingual, LegitScript-certified compounded GLP-1.
Visit REMEViNP2GO
Shoppers inside its 40 served states who want both molecules disclosed and will vet the pharmacy themselves.
Visit NP2GOThe verdict
REMEVi takes it, leading the Cost-Efficiency Index 80 to 79. REMEVi is the first bilingual (English and Spanish) GLP-1 telehealth clinic — care delivered by clinicians trained in both languages, never auto-translated. NP2GO still earns a C — Shoppers inside its 40 served states who want both molecules disclosed and will vet the pharmacy themselves.
Worth knowing either way: our overall #1 pick is CoreAge Rx (Cost-Efficiency Index 94/100 — the top of the ranking). See how it stacks up: CoreAge Rx vs REMEVi.
Factor by factor
Both providers scored on our six Cost-Efficiency Index factors. The stronger side on each row is marked in teal.
Normalized Cost/Month
Price Transparency
Nationwide Access
Formulation Options
Clinical Oversight
Contract Flexibility
Pricing, coverage & formulary
The disclosed facts behind the scores. Lower price wins its row (teal).
| Spec | REMEVi | NP2GO |
|---|---|---|
| Cost-Efficiency Index | 80/100 | 79/100 |
| Semaglutide / mo | $219/mo | $150/mo |
| Tirzepatide / mo | $319/mo | $250/mo |
| Semaglutide / yr (modeled) | $2,628 | $1,800 |
| Tirzepatide / yr (modeled) | $3,828 | $3,000 |
| Coverage | All 50 states | AK, AZ, AR, CA, CO, CT, DE, DC, FL, HI, ID, IL, IA, KS, KY, ME, MD, MA, MI, MN, MT, NE, NV, NH, NJ, NM, NY, ND, OK, OR, PA, RI, SD, TX, UT, VT, VA, WA, WV, WY |
| Oral / sublingual | Yes | No |
| Brand-name access | Compounded only | Compounded only |
| Rank here | #31 | #33 |
REMEVi
80/100Where the value is
- A genuinely flat rate: 'the same price at every dose', stated as such, with no dose upcharge and no introductory rate to step off
- Longer terms are published openly rather than used as a teaser — semaglutide falls to $189 on 12 weeks and $149 on 52
- A daily oral semaglutide tablet is offered alongside the injection
The tradeoffs
- The flat rate is the highest entry price of the top-scoring programs here; the cheaper $149 figure needs a full year
- No FDA-approved brand-name pathway — the Wegovy and Ozempic pages are comparison content, not products
NP2GO
79/100Where the value is
- Both molecules disclosed — $150 semaglutide / $250 tirzepatide — for straightforward cost modeling
- Broad 40-state footprint — wider than most non-nationwide operators
- Flat, predictable pricing
The tradeoffs
- 40 states, not all 50 — a coverage gamble that dents its access score
- Not LegitScript-certified — oversight harder to verify
Assume any provider we list may compensate us — we may earn a commission, at no cost to you. It never changes the Cost-Efficiency Index. Pricing, states and verification reflect each provider's public disclosures at last review; prices change — confirm on the provider's site. Not medical advice. See our disclosure.